Procaps Group, SA 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
Sofgen Pharma, S.A. reports significant financial losses for 2024, Nasdaq delisting, and material weaknesses in internal controls, while completing a major debt restructuring and capital raise post-year-end.